New insights into the activation, interaction partners and possible functions of MK5/PRAK

Maria Perander, Stephen M. Keyse, Ole-Morten Seternes (Lead / Corresponding author)

    Research output: Contribution to journalArticle

    1 Citation (Scopus)

    Abstract

    MAP kinase-activated protein kinase 5 (MK5) was first described as a downstream target of the p38 MAP kinase pathway leading to its alternative acronym of p38-regulated/activated protein kinase (PRAK). However, since the discovery that MK5 is a bona fide interaction partner of the atypical MAP kinases ERK3 and ERK4 and that this interaction leads to both the activation and subcellular relocalisation of MK5, there has been considerable debate as to the relative roles of these MAPK pathways in mediating the activation and biological functions of MK5. Here we discuss recent progress in defining novel upstream components of the ERK3/ERK4 signalling pathway, our increased understanding of the mechanism by which MK5 interacts with and is activated by ERK3 and ERK4, and the discovery of novel interaction partners for MK5. Finally, we review recent literature that suggests novel biological functions for MK5 in a range of physiological and pathophysiological conditions including neuronal function and cancer.

    Original languageEnglish
    Pages (from-to)374-384
    Number of pages11
    JournalFrontiers in Bioscience
    Volume21
    Issue number2
    DOIs
    Publication statusPublished - 1 Jan 2016

    Fingerprint

    Protein Kinases
    Mitogen-Activated Protein Kinase 6
    Chemical activation
    MAP Kinase Signaling System
    p38 Mitogen-Activated Protein Kinases
    Phosphotransferases
    Neoplasms
    MAP-kinase-activated kinase 5

    Keywords

    • Cytoplasm
    • Enzyme activation
    • Humans
    • Intracellular signaling peptides and proteins
    • Phosphorylation
    • Protein binding
    • Protein-Serine-Threonine Kinases
    • Signal transduction
    • Substrate specificity
    • Journal article
    • Research support, Non-U.S. Gov't
    • Review

    Cite this

    @article{d5505dc5a3d54bb4b80518e74c0d80a4,
    title = "New insights into the activation, interaction partners and possible functions of MK5/PRAK",
    abstract = "MAP kinase-activated protein kinase 5 (MK5) was first described as a downstream target of the p38 MAP kinase pathway leading to its alternative acronym of p38-regulated/activated protein kinase (PRAK). However, since the discovery that MK5 is a bona fide interaction partner of the atypical MAP kinases ERK3 and ERK4 and that this interaction leads to both the activation and subcellular relocalisation of MK5, there has been considerable debate as to the relative roles of these MAPK pathways in mediating the activation and biological functions of MK5. Here we discuss recent progress in defining novel upstream components of the ERK3/ERK4 signalling pathway, our increased understanding of the mechanism by which MK5 interacts with and is activated by ERK3 and ERK4, and the discovery of novel interaction partners for MK5. Finally, we review recent literature that suggests novel biological functions for MK5 in a range of physiological and pathophysiological conditions including neuronal function and cancer.",
    keywords = "Cytoplasm, Enzyme activation, Humans, Intracellular signaling peptides and proteins, Phosphorylation, Protein binding, Protein-Serine-Threonine Kinases, Signal transduction, Substrate specificity, Journal article, Research support, Non-U.S. Gov't, Review",
    author = "Maria Perander and Keyse, {Stephen M.} and Ole-Morten Seternes",
    note = "Work in the Keyse laboratory is supported by a programme grant from Cancer Research UK (CR-UK Stress Response Laboratory C8227/A12053). Work in the Seternes laboratory is supported by grant from the Aakre foundation.",
    year = "2016",
    month = "1",
    day = "1",
    doi = "10.2741/4394",
    language = "English",
    volume = "21",
    pages = "374--384",
    journal = "Frontiers in Bioscience",
    issn = "1093-9946",
    publisher = "Frontiers in Bioscience",
    number = "2",

    }

    New insights into the activation, interaction partners and possible functions of MK5/PRAK. / Perander, Maria; Keyse, Stephen M.; Seternes, Ole-Morten (Lead / Corresponding author).

    In: Frontiers in Bioscience, Vol. 21, No. 2, 01.01.2016, p. 374-384.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - New insights into the activation, interaction partners and possible functions of MK5/PRAK

    AU - Perander, Maria

    AU - Keyse, Stephen M.

    AU - Seternes, Ole-Morten

    N1 - Work in the Keyse laboratory is supported by a programme grant from Cancer Research UK (CR-UK Stress Response Laboratory C8227/A12053). Work in the Seternes laboratory is supported by grant from the Aakre foundation.

    PY - 2016/1/1

    Y1 - 2016/1/1

    N2 - MAP kinase-activated protein kinase 5 (MK5) was first described as a downstream target of the p38 MAP kinase pathway leading to its alternative acronym of p38-regulated/activated protein kinase (PRAK). However, since the discovery that MK5 is a bona fide interaction partner of the atypical MAP kinases ERK3 and ERK4 and that this interaction leads to both the activation and subcellular relocalisation of MK5, there has been considerable debate as to the relative roles of these MAPK pathways in mediating the activation and biological functions of MK5. Here we discuss recent progress in defining novel upstream components of the ERK3/ERK4 signalling pathway, our increased understanding of the mechanism by which MK5 interacts with and is activated by ERK3 and ERK4, and the discovery of novel interaction partners for MK5. Finally, we review recent literature that suggests novel biological functions for MK5 in a range of physiological and pathophysiological conditions including neuronal function and cancer.

    AB - MAP kinase-activated protein kinase 5 (MK5) was first described as a downstream target of the p38 MAP kinase pathway leading to its alternative acronym of p38-regulated/activated protein kinase (PRAK). However, since the discovery that MK5 is a bona fide interaction partner of the atypical MAP kinases ERK3 and ERK4 and that this interaction leads to both the activation and subcellular relocalisation of MK5, there has been considerable debate as to the relative roles of these MAPK pathways in mediating the activation and biological functions of MK5. Here we discuss recent progress in defining novel upstream components of the ERK3/ERK4 signalling pathway, our increased understanding of the mechanism by which MK5 interacts with and is activated by ERK3 and ERK4, and the discovery of novel interaction partners for MK5. Finally, we review recent literature that suggests novel biological functions for MK5 in a range of physiological and pathophysiological conditions including neuronal function and cancer.

    KW - Cytoplasm

    KW - Enzyme activation

    KW - Humans

    KW - Intracellular signaling peptides and proteins

    KW - Phosphorylation

    KW - Protein binding

    KW - Protein-Serine-Threonine Kinases

    KW - Signal transduction

    KW - Substrate specificity

    KW - Journal article

    KW - Research support, Non-U.S. Gov't

    KW - Review

    U2 - 10.2741/4394

    DO - 10.2741/4394

    M3 - Article

    VL - 21

    SP - 374

    EP - 384

    JO - Frontiers in Bioscience

    JF - Frontiers in Bioscience

    SN - 1093-9946

    IS - 2

    ER -